logologologologo
  • Home
  • Business
  • Markets
  • Exchange
  • Investment
  • Personal Finance

Buffett’s Berkshire cuts U.S. drugmaker stakes, invests in drug royalty company

Warren Buffett’s Berkshire Hathaway Inc said on Monday it eliminated its investment in Merck & Co and reduced its stakes in AbbVie Inc and Bristol-Myers Squibb Co, as it pared its overall stock market investments.

Berkshire also eliminated its small stakes in Organon & Co, a Merck spinoff specializing in contraception and other women’s health products, and telecommunications company Liberty Global Plc.

It disclosed new investments of $475 million in Royalty Pharma Plc, which buys drug royalties, and $99 million in flooring retailer Floor & Decor Holdings Inc.

The changes were disclosed in a regulatory filing detailing Berkshire’s U.S.-listed holdings as of Sept. 30.

Shares of Royalty Pharma rose more than 5% after the market close, a common occurrence after Berkshire reveals new stakes. Royalty Pharma did not immediately respond to requests for comment.

Investors monitor Berkshire’s investments closely to see where Buffett and his investment managers Todd Combs and Ted Weschler see value. The filings do not say who bought and sold what, though Buffett generally handles larger investments.

While Berkshire ended September with $310.7 billion of equity holdings, it sold $2 billion more stocks than it bought in the third quarter, and has been a net seller for all of 2021.

About 41% of Berkshire’s stock investments are in Apple, with another 29% in Bank of America Corp, American Express Co and Coca-Cola Co.

The sales and Buffett’s nearly six-year drought in buying large whole companies have contributed to Berkshire’s boosting its cash holdings to a record https://www.reuters.com/article/berkshire-results-idCAKBN2HR092 $149.2 billion, despite at least $21.9 billion of stock buybacks this year.

They have also disappointed investors who have seen Berkshire’s stock price significantly lag the Standard & Poor’s 500 since the end of 2018.

Berkshire’s respective share stakes in AbbVie and Bristol-Myers fell 30% and 16% in the quarter.

Royalty Pharma helps fund late-stage clinical trials and product launches in exchange for future royalty streams, and sometimes buys royalties from drug developers.

Its larger revenue streams come from Vertex Pharmaceuticals Inc treatments for cystic fibrosis, Biogen Inc’s Tysabri for multiple sclerosis, and AbbVie’s Imbruvica for various cancers.

The company’s share price has recently traded about 50% above its initial public offering price in June 2020, but below where it closed on its first trading day.

Berkshire is based in Omaha, Nebraska. It also owns dozens of businesses including the BNSF railroad, Geico auto insurance and Dairy Queen ice cream.

Related posts

February 3, 2023

Where Will AMD Stock Be In 1 Year?


Read more

Categories

  • Business
  • Content
  • Exchange
  • Inflation
  • Investment
  • Markets
  • Personal Finance
  • Technology
  • Uncategorized

Archives

  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021

Recent Posts

  • Where Will AMD Stock Be In 1 Year?
  • Here’s how — and where — Netflix has started cracking down on password sharing
  • 2 reasons Meta stock is exploding 20% after a whopper earnings miss
  • Apple earnings: What to expect from the iPhone maker
  • Bitcoin closes out best January since 2013

About Us

The Alpha Cut a Vida Street LLC Company
1404 N. Ronald Reagan Blvd.
Suite 1120
Longwood, FL 32750

Link

(843) 256-4375
https://thealphacut.com

Why Us

Terms & Privacy
Policy & Procedure
Disclaimer

This material is not an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only.
Any performance results discussed herein represent past performance, not a guarantee of future performance, and are not indicative of any specific investment. Due to the timing of information presented, investment performance may be adjusted after the publication of this report. There can be no assurance that the future performance of any specific investment, investment strategy, or product made reference to directly or indirectly in this communication will be profitable, equal any corresponding indicated historical performance levels or be suitable for your portfolio.
All data in this communication is provided for informational purposes only and is not intended for trading or investing purposes. We expressly disclaim the accuracy, adequacy, or completeness of any data and content provided by financial exchanges, individual issuers, their respective affiliates and business partners and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. You agree not to copy, modify, reformat, download, store, reproduce, reprocess, transmit or redistribute any data or information found herein or use any such data or information in a commercial enterprise without obtaining our prior written consent.
We make no express or implied warranties or representations and shall have no liability whatsoever with respect to any data contained herein. The data may not be further redistributed or used to create indices or other financial products. This report and the views expressed herein are subject to change at any time based upon market or other conditions (such as domestic and global economic trends) and are current as of the date of publication hereof. The information, analysis, and opinions expressed herein are for general information only and are not intended to provide specific advice or recommendations for any individual or entity.
We emphasize that Investment in the securities of smaller companies can involve greater risk than is generally associated with investment in larger, more established companies, and can result in significant capital losses that may have a detrimental effect on the value of your investments.
Forecasting represents predictions of market prices and/or volume patterns utilizing varying analytical data. It is not representative of a projection of the stock market, or of any specific investment.
Nothing contained in this material is intended to constitute legal, tax, securities or investment advice, nor an opinion regarding the appropriateness of any investment. The general information contained in this publication should not be acted upon without obtaining specific legal, tax and investment advice from a licensed professional.
Please remember that all investments carry some level of risk, including the potential loss of principal invested. They do not typically grow at an even rate of return and may experience negative growth.As with any structuring of a portfolio of investments, attempting to reduce risk and increase return could, at certain times, unintentionally reduce returns.
The information, analysis and opinions expressed herein are for general, impersonal information only and are not intended to provide specific advice or recommendations for any individual entity.

copyright © Alpha Cut 2021. All Right Reserved
The Alpha Cut a Vida Street LLC Company